Effect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure.

NCT07605260 | Completed

• 1 other identifier: Dr-Irtiza-Islamabad
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Local data regarding the effectiveness and safety of mannitol has been scarce. Therefore, the current study was planned, aiming to compare the change in mean anterior chamber depth and intraocular pressure (IOP) and to determine the frequencies of perioperative complications during cataract surgery in groups receiving mannitol versus placebo.

Conditions

Cataract

Outcome Measures

Primary Outcomes (2)

• Change in the intraocular pressure

  The change in the intraocular pressure, measured in mmHg, was noted at post-intervention and compared to the baseline.

  45 minutes

• Change in the anterior chamber depth

  The change in the anterior chamber depth, measured in mm, was noted at post-intervention and compared to the baseline.

  45 minutes

Study Arms (2)

Group-A

EXPERIMENTAL

After employing standard protocol for dilatation, intravenous mannitol at 1g/kg over a period of 30 minutes was administered to the patients.

Drug: Mannitol

Group-B

PLACEBO COMPARATOR

After employing standard protocol for dilatation, patients were given a placebo.

Drug: Placebo

Interventions

Mannitol DRUG

After employing standard protocol for dilatation, intravenous mannitol at 1g/kg over a period of 30 minutes was administered to the patients.

Group-A

Placebo DRUG

After employing standard protocol for dilatation, patients were given a placebo.

Group-B

Eligibility Criteria

• Age: 30 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients of any gender
• Aged 30-80 years
• Undergoing cataract surgery

You may not qualify if:

• Patients with glaucoma, uveitis, or corneal pathology
• With trauma
• Previously had surgery
• With exfoliation syndrome
• Had iridotomies
• Had use of sympathetic α1 antagonist

Sponsors & Collaborators

• Muhammad Aamir Latif: lead

Study Sites (1)

Pakistan Air Force (PAF) hospital

Islamabad, Punjab Province, 44000, Pakistan

Location

MeSH Terms

Conditions

Cataract

Interventions

Mannitol

Condition Hierarchy (Ancestors)

Lens Diseases; Eye Diseases

Intervention Hierarchy (Ancestors)

Sugar Alcohols; Alcohols; Organic Chemicals; Carbohydrates

Study Officials

• Muhammad Irtiza

  Pakistan Air Force (PAF) Hospital Islamabad

  PRINCIPAL INVESTIGATOR

• Muhammad Azam, FCPS

  Pakistan Air Force (PAF) Hospital Islamabad

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Research Consultant

Study Record Dates

• First Submitted: May 18, 2026
• First Posted: May 22, 2026
• Study Start: September 1, 2024
• Primary Completion: February 28, 2025
• Study Completion: February 28, 2025
• Last Updated: May 22, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)